Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Study of the Combination of Ipilimumab and Fotemustine in Patients With Unresectable Locally Advanced or Metastatic Malignant Melanoma
Brief Summary: This study is designed to assess the safety and efficacy of a combination of ipilimumab and fotemustine in Patients with Unresectable Locally Advanced or Metastatic Malignant Melanoma.


Options:
A: Arm Label: Arm A consists of 3 phases or steps; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab - Arm A | Arm Label: Arm B consists of 3 phases or steps; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab + Ipilimumab - Arm B | Intervention Type: DRUG; Name: Nivolumab - Arm A; Assigned to Arm(s): Arm A consists of 3 phases or steps | Intervention Type: DRUG; Name: Nivolumab + Ipilimumab - Arm B; Assigned to Arm(s): Arm B consists of 3 phases or steps
B: Arm Label: Nivolumab, 3 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: BMS-936558 (Nivolumab), Drug: Placebo matching Dacarbazine | Arm Label: Dacarbazine, 1000 mg/m^2; Type: ACTIVE_COMPARATOR; Interventions: Biological: Placebo matching BMS-936558 (Nivolumab), Drug: Dacarbazine | Intervention Type: BIOLOGICAL; Name: BMS-936558 (Nivolumab); Assigned to Arm(s): Nivolumab, 3 mg/kg | Intervention Type: BIOLOGICAL; Name: Placebo matching BMS-936558 (Nivolumab); Assigned to Arm(s): Dacarbazine, 1000 mg/m^2 | Intervention Type: DRUG; Name: Dacarbazine; Assigned to Arm(s): Dacarbazine, 1000 mg/m^2 | Intervention Type: DRUG; Name: Placebo matching Dacarbazine; Assigned to Arm(s): Nivolumab, 3 mg/kg
C: Arm Label: Arm I (paclitaxel, carboplatin, sorafenib tosylate); Type: EXPERIMENTAL; Interventions: Drug: Carboplatin, Other: Laboratory Biomarker Analysis, Drug: Paclitaxel, Other: Pharmacological Study, Drug: Sorafenib Tosylate | Arm Label: Arm II (carboplatin, paclitaxel, placebo); Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Other: Laboratory Biomarker Analysis, Drug: Paclitaxel, Other: Pharmacological Study, Other: Placebo | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Arm I (paclitaxel, carboplatin, sorafenib tosylate), Arm II (carboplatin, paclitaxel, placebo) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm I (paclitaxel, carboplatin, sorafenib tosylate), Arm II (carboplatin, paclitaxel, placebo) | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm I (paclitaxel, carboplatin, sorafenib tosylate), Arm II (carboplatin, paclitaxel, placebo) | Intervention Type: OTHER; Name: Pharmacological Study; Assigned to Arm(s): Arm I (paclitaxel, carboplatin, sorafenib tosylate), Arm II (carboplatin, paclitaxel, placebo) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Arm II (carboplatin, paclitaxel, placebo) | Intervention Type: DRUG; Name: Sorafenib Tosylate; Assigned to Arm(s): Arm I (paclitaxel, carboplatin, sorafenib tosylate)
D: Arm Label: Single arm of ipilimumab and fotemustine; Type: EXPERIMENTAL; Interventions: Drug: Ipilimumab and Fotemustine | Intervention Type: DRUG; Name: Ipilimumab and Fotemustine; Assigned to Arm(s): Single arm of ipilimumab and fotemustine

Answer: D